Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting
"Our expanding product portfolio provides a comprehensive view of both the tumor microenvironment and the dynamic immune response, delivering new approaches to answer critical questions linked to cancer research and potential treatment paradigms," said Chris Linthwaite, President and CEO of Fluidigm. "We are inspired by the impressive results of our customers and the data they will present at AACR. They are providing new insights, identifying informative biomarkers and accelerating the development of better immunotherapies. We will share the details of multiple transformative innovations offered by
Featured Immuno-Oncology and Cancer Research Applications
- Announced today, the Maxpar® Direct™ Immune Profiling System is the first complete sample-to-answer solution for deep immune cell profiling, essential for investigating immune response, and accelerating the development of new immunotherapies. Developed for use with Fluidigm® CyTOF® technology, the system empowers researchers to quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using a simple single-tube workflow with automated five-minute results reporting.
An introduction to the Maxpar Direct Immune Profiing System will be presented on
Monday, April 1, by Stephen Li, PhD, of Fluidigmin a poster titled, “A robust human immune profiling assay using CyTOF® technology and automated data analysis software” (P1667). Additional presentations on the Maxpar Direct Immune Profiling System will be given daily at Fluidigm Booth 1523 from Sunday, March 31, to Wednesday, April 3. See schedule for details.
- The Hyperion™ Imaging System provides an ideal solution for deep interrogation of the tissue and tumor microenvironment, enabling simultaneous imaging of up to 37 protein markers from a single scan of formalin-fixed, paraffin-embedded (FFPE) or fresh tumor sections using Imaging Mass Cytometry™. Enabling high-dimensional profiling of cell phenotypes and function in the spatial context of the tissue microenvironment, Imaging Mass Cytometry is powering new breakthroughs globally with more than 20 scientific publications and an established footprint of more than 50 commercially enabled systems in more than 10 different countries.
- The Juno™ and Biomark™ HD automated microfluidic systems enable highly efficient detection of somatic mutations, gene fusions and immuno-oncology gene expression signatures from FFPE tissues while ensuring consistent performance and high-quality results.
Preliminary results from two exciting Advanta™ oncology assays in development will be shared starting on
Sunday, March 31. Thomas Goralski, PhD, of Fluidigmwill present a poster titled, “Development of a comprehensive gene fusion NGS panel using an integrated microfluidic circuit enabling highly efficient multiplex PCR enrichment” (P745). Additional presentations on these oncology assays will be given daily at Fluidigm Booth 1523 from Sunday, March 31, to Wednesday, April 3. See schedule for details.
Starting Sunday, March 31, at AACR 2019, several leading translational and clinical researchers will present on the development of predictive biomarkers of cancer progression and therapeutic response using
Kara Davis, DO, of Stanford University, a leading researcher who has identified predictive signatures of leukemia relapse using mass cytometry will present the use of high-dimensional single-cell mass cytometry in translational cancer research on March 31. Bernd Bodenmiller, PhD, of the University of Zurich, a key innovator in Imaging Mass Cytometry, will present the identification of tumor ecosystems that correlate with poor prognosis and immunosuppression on April 3.
Multiple poster presenters from leading academic medical centers and pharma will also share their recent accomplishments using Fluidigm technologies. A few examples include:
Mahesh Yadav, PhD, of Genentech will present results demonstrating that the enrichment of late-differentiated effector neoantigen-specific CD8+ T cells in non-small cell lung cancer patients by mass cytometry correlates with atezolizumab treatment response (P4055). Monirath Hav, MD, PhD, of the University of Southern Californiawill present new insights gained through Imaging Mass Cytometry into immune cell composition and spatial heterogeneity in diffuse large B cell lymphoma associated with treatment outcome (P502).
- Maria-Fernanda Senosian of
Vanderbilt Universitywill present results demonstrating the use of mass cytometry to distinguish indolent from aggressive lung adenocarcinomas (P4701).
Fluidigm will be hosting an informative customer dinner event on
More information on the Fluidigm products and research presentations and posters at AACR using Fluidigm technologies can be found at Fluidigm Booth 1523 or at fluidigm.com/events/aacr-2019.
Forward-Looking Statement for
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and the growth and potential of immune profiling and
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation